GI-6301 clinical trials
Also written GI-6301.
- studies test it
- 18
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses GI-6301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GI-6301
- 16
Studies by the year they started
18 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 6 |
| 2018 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 1
ImmunityBio, Inc. (16) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (16) · ETBX-051 (16) · ETBX-061 (16) · ETBX-011 (13) · GI-4000 (13) · Yeast-CEA vaccine (12) · ETBX-021 (8) · Albumin-Bound Paclitaxel (1)
Studies
Open first, then newest update. How each study uses GI-6301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as GI-6301
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as GI-6301
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as GI-6301
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as GI-6301
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnPhase 1/2ImmunityBio, Inc.NCT03647423Written as GI-6301
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167164Written as GI-6301
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as GI-6301
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as GI-6301
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as GI-6301
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as GI-6301
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as GI-6301
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as GI-6301
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as GI-6301
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as GI-6301
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as GI-6301
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine ChordomaCompletedPhase 2NantCell, Inc.NCT02383498Written as GI-6301 Vaccine (Yeast- Brachyury)
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as GI-6301
- Cancer Vaccine Targeting Brachyury Protein in TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01519817Written as GI-6301 (Yeast Brachyury Vaccine)
Given beside what is tested · 1 — GI-6301 is usual care or a partner of the new treatment
Codes
What other systems call GI-6301 · ClinicalTrials.gg INT016053
- UNII (FDA) B0L24T8TB7GI-6301One source FDA
- NCI Thesaurus C106267Brachyury-expressing Yeast Vaccine GI-6301One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B0L24T8TB7 | GI-6301 | One source FDA |
| NCI Thesaurus | C106267 | Brachyury-expressing Yeast Vaccine GI-6301 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.